同步放化疗与序贯放化疗治疗中晚期食管癌的临床研究

目的 比较同步放化疗与序贯放化疗治疗中晚期食管癌的近期疗效和长期生存率.方法 168例中晚期食管癌患者随机分为两组:同步放化疗组91例；序贯放化疗组77例.同步放化疗组:放疗2 Gy/次,总量50～ 56 Gy.同步化疗2周期,放疗结束后继续化疗4周期；序贯放化疗组:放疗2 Gy/次,总量60 ～64 Gy.待放疗结...

Clinical Research of Concurrent Chemoradiotherapy and Sequential Chemoradiotherapy of Advanced Esophageal Carcinoma

Objective To study the short term effect and long term survival rate of concurrent chemoradiotherapy and sequential chemoradiotherapy of advanced esophageal carcinoma. Methods All the 168 patients with advanced esophageal carcinoma were randomly divided into two groups.The 91 cases in the concurrent chemoradiotherapy group: radiotherapy 2 Gy/time,the volume dose was 50-56 Gy;2 cycles of chemotherapy were given at the same time,4 cycles of chemotherapy were given after the radiotherapy.The 77 cases in the sequential chemoradiotherapy group: radiotherapy 2 Gy/time,the volume dose was 60-64 Gy;6 cycles of chemotherapy were given after the radiotherapy.The chemotherapy regimens of the two groups were the same: DDP 20 mg/m2,intervenous drop infusion,d1-5;tegafur 400 mg/m2,intervenous drop infusion,d1-5. Results The effective rate of the concurrent chemoradiotherapy group was 67.0%,and that of the sequential chemoradiotherapy group was 59.7%(P>0.05).The 1-,3-year survival rates of the concurrent chemoradiotherapy group were 73.6% and 49.5%,those of the sequential chemoradiotherapy group were 45.5% and 24.7%(P<0.05).The toxicities of the two groups were indiscriminate,and could be tolerated. Conclusion The short term effect of concurrent chemoradiotherapy and sequential chemoradiotherapy are good for advanced esophageal carcinoma,and their toxicities can be tolerated;concurrent chemoradiotherapy has an advantage in the long term survival.